clinicaltrialvanguard

20 Hours Back Per Activation: What WCG’s New Tool Reveals About the Real Cost of Manual Study Startup

WCG's Activation Intelligence saves 20+ hours per study activation. Here's what that number means for site startup budgets ...
clinicaltrialvanguard

Proteomic Aging Clocks Enter Clinical Trials: What Sponsors Need to Know Before the FDA Does

Proteomic aging clocks are moving into clinical trials, but FDA surrogate endpoint standards and assay reproducibility gaps ...
clinicaltrialvanguard

Phase IV heart failure studies use digital tools to address patient dropout from low perceived benefit

Heart failure Phase IV studies use digital tools and remote monitoring to reduce patient dropout when perceived personal ...
clinicaltrialvanguard

FDA Grants Priority Review to BridgeBio’s Oral Infigratinib for Pediatric Achondroplasia

FDA grants priority review to BridgeBio's oral infigratinib for pediatric achondroplasia, offering a once-daily pill ...
clinicaltrialvanguard

Zenas BioPharma releases Phase 3 obexelimab data in IgG4-related disease

Zenas BioPharma releases Phase 3 obexelimab IgG4-related disease data with open-label extension results showing durability ...